My new pinned tweet, #NWBO. #future

@GlSpeir Please research NWBO and its DCVax-L personal vaccine for GBM....Dr. Linda Liau at UCLA as well. Good luck

$NWBO Okay, I have new information from MHRA regarding all the November 2025 CTBVEAG and CHM discussion. Based on this email I got today my thoughts now changed since the Licensing section of CTBVEAG according to "MHRA CTBVEAG provides expert advice on clinical trials only. They do not advise on licensing decisions, approval likelihood, or pre‑CHM positions. Any references to licensing in their discussions relate only to the context of clinical development, not to Marketing Authorisation assessment." My initial bias was all based on Licensing and CTA as two different processes within the meeting minutes, now that has been cleared up it seems only the CHM minutues was possibly relevent to DCVAX. I have no issue going back on my initial discussion if I find out additional details to warrant so. Hope this helps investors with that long discussion over last few weeks.

BP, do you want to buy closed loop system, grade c flaskworks = higher profit margin, mhra de-risking, control from vein to vein. Science is amazing, Kalinsky IP makes it even better. Puzzle pieces coming together in 2026. Jenkins... NWBO.

🥳🥳🥳

Recent tizzy on #NWBO is much to do about nothing... IMO

The focus is not necessarily median OS, it is increasing long term survival rates, NWBO DCVax fat tail and getting fatter is where it is at.

NWBO would not commit resources to transferring tech to US CDMO if not feeling secure about MHRA approval.

Maybe Adam would like a flat across the street from Advent so he can see the good that NWBO is doing for the world. Difficult to see humanity's good works from your mom's basement.

Adam unknowingly brings up a good point to NWBO investors, NWBO owns a sizable lot of land across from Advent Bioservices that they could sell to residential land developers for $ to fund future manufacturing buildout. I hope he makes it out of his mom's basement one day.

NWBO transfer of tech to US CDMO in preparation for FDA application for DCVax-L. Setup for product manufacturing distribution IP sale to future BP. Kalinski IP research in parallel to DCVax. Personalized dendritic cells PD1 inhibitor. Massively undervalued upside.

#dcvax $nwbo #gbm Some interesting synergy with these industry updates of companies in the session that George Zavoico, PhD, $nwbo chairs with analysis below along with details of day 2 Opening keynote address by Ira Mellman PhD, Parker Institute for Cancer Immunotherapy Agenda Frontiers in Cancer Immunotherapy Monday, 22 June 2026, 08:30 - Tuesday, 23 June 2026, 17:20 Session II: Brief Industry Updates Chairperson: George Zavoico, PhD, Northwest Biotherapeutics 12:45 Metabolic mechanisms of resistance to cancer vaccination Lisa Butterfield, PhD, Consultant 1:05 PM Leveraging Synthetic Antigens to Create Universal Immunotherapies for Solid Tumors Lex Johnson, PhD, Dispatch Bio 1:25 PM Robert Fenstermaker, MD, MimiVax 1:45 PM Introducing Normunity’s Immuno-Smart Targets: Novel Immuno-Relevant Tumor-Specific Targets to Optimize the Safety and Efficacy of Payload-Carrying Biologics Rachel Humphrey, MD, Normunity The presentations scheduled for this session offer several points of technical synergy with the DCVax (L-Dendritic Cell) platform technology, particularly regarding the enhancement of its efficacy within the immunosuppressive tumor microenvironment. Synergies with DCVax Platform Technology 1. Overcoming Metabolic Resistance (Dr. Lisa Butterfield)A primary challenge for dendritic cell vaccines like DCVax-L is the metabolic hostility of the tumor microenvironment (TME). Tumors often deplete essential nutrients (like glucose and amino acids) and produce immunosuppressive metabolites (such as lactic acid), which can impair the maturation and function of the injected dendritic cells. Synergy: Understanding these metabolic "brakes" could lead to combination protocols where DCVax-L is administered alongside metabolic inhibitors. This would ensure that the dendritic cells can effectively prime T-cells without being silenced by the tumor's metabolic defenses. 2. Universal Immunotherapies and Synthetic Antigens (Dr. Lex Johnson)DCVax-L is inherently personalized, utilizing the full spectrum of a patient’s own tumor lysate (proteome). Synergy: Research into synthetic antigens could complement the DCVax approach by providing "booster" targets. If universal antigens can be identified that are common across solid tumors, they could potentially be loaded onto the DCVax platform alongside the patient-specific lysate to ensure a more robust and sustained immune response. 3. Targeting the "Immuno-Smart" Proteome (Dr. Rachel Humphrey)Normunity’s focus on tumor-specific targets for payload-carrying biologics (like ADCs) aligns with the need for precision. Synergy: If "Immuno-Smart" targets can identify specific vulnerabilities in the tumor's exterior, these could be used as markers to track the success of DCVax-induced T-cell infiltration. Furthermore, using biologics to "de-bulk" or weaken the tumor's structural integrity could make it more susceptible to the systemic immune surge triggered by a dendritic cell vaccine. Strategic Context: Dr. George Zavoico and NWBO The presence of Dr. George Zavoico as the Chairperson for this specific session is significant for Northwest Biotherapeutics ($NWBO) for several reasons: Scientific Leadership: As a PhD and a key figure at Northwest Biotherapeutics, Zavoico’s role in moderating these specific topics—resistance mechanisms, synthetic antigens, and novel targets—places $NWBO at the center of the conversation regarding the next generation of immunotherapy. Integrated Approaches: His oversight of these "Brief Industry Updates" suggests a strategic interest in how DCVax might integrate with these emerging technologies. For example, if DCVax-L provides the "engine" for the immune response, the technologies presented by Normunity or Dispatch Bio might provide the "navigation" or "fuel" to overcome localized resistance. Validation: Serving as a chairperson at a New York Academy of Sciences (NYAS) event reinforces the company’s standing within the academic and regulatory community, particularly as they navigate the transition from clinical trials to potential market integration and synergistic trial designs. Day 2 - Opening Keynote Address 9:05 AM The coming renaissance of cancer immunotherapy Ira Mellman, PhD, Parker Institute for Cancer Immunotherapy events.nyas.org/cancerio26/a…

Just to be clear, I could care less what the #NWBO daily up and down is, what I care about is the final price big pharma wants for my shares. Glad I accumulated while it was around 0.20 and would be happy for shorts and MM to push it down once more. MMs lazy POS, get it down!